Copyright Reports & Markets. All rights reserved.

Global MRD (Minimal Residual Disease) Testing Market Research Report 2021

Request for Sample of this report
Buy now

1 MRD (Minimal Residual Disease) Testing Market Overview

  • 1.1 Product Overview and Scope of MRD (Minimal Residual Disease) Testing
  • 1.2 MRD (Minimal Residual Disease) Testing Segment by Type
    • 1.2.1 Global MRD (Minimal Residual Disease) Testing Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Flow Cytometry
    • 1.2.3 Polymerase Chain Reaction (PCR)
    • 1.2.4 Next-Generation Sequencing (NGS)
  • 1.3 MRD (Minimal Residual Disease) Testing Segment by Application
    • 1.3.1 Global MRD (Minimal Residual Disease) Testing Sales Comparison by Application: (2021-2027)
    • 1.3.2 Specialty Clinics and Hospitals
    • 1.3.3 Diagnostic Laboratories
    • 1.3.4 Research Institutions
  • 1.4 Global MRD (Minimal Residual Disease) Testing Market Size Estimates and Forecasts
    • 1.4.1 Global MRD (Minimal Residual Disease) Testing Revenue 2016-2027
    • 1.4.2 Global MRD (Minimal Residual Disease) Testing Sales 2016-2027
    • 1.4.3 MRD (Minimal Residual Disease) Testing Market Size by Region: 2016 Versus 2021 Versus 2027

2 MRD (Minimal Residual Disease) Testing Market Competition by Manufacturers

  • 2.1 Global MRD (Minimal Residual Disease) Testing Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global MRD (Minimal Residual Disease) Testing Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers MRD (Minimal Residual Disease) Testing Manufacturing Sites, Area Served, Product Type
  • 2.5 MRD (Minimal Residual Disease) Testing Market Competitive Situation and Trends
    • 2.5.1 MRD (Minimal Residual Disease) Testing Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest MRD (Minimal Residual Disease) Testing Players Market Share by Revenue
    • 2.5.3 Global MRD (Minimal Residual Disease) Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 MRD (Minimal Residual Disease) Testing Retrospective Market Scenario by Region

  • 3.1 Global MRD (Minimal Residual Disease) Testing Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.2 Global MRD (Minimal Residual Disease) Testing Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.3 North America MRD (Minimal Residual Disease) Testing Market Facts & Figures by Country
    • 3.3.1 North America MRD (Minimal Residual Disease) Testing Sales by Country
    • 3.3.2 North America MRD (Minimal Residual Disease) Testing Revenue by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe MRD (Minimal Residual Disease) Testing Market Facts & Figures by Country
    • 3.4.1 Europe MRD (Minimal Residual Disease) Testing Sales by Country
    • 3.4.2 Europe MRD (Minimal Residual Disease) Testing Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific MRD (Minimal Residual Disease) Testing Market Facts & Figures by Region
    • 3.5.1 Asia Pacific MRD (Minimal Residual Disease) Testing Sales by Region
    • 3.5.2 Asia Pacific MRD (Minimal Residual Disease) Testing Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America MRD (Minimal Residual Disease) Testing Market Facts & Figures by Country
    • 3.6.1 Latin America MRD (Minimal Residual Disease) Testing Sales by Country
    • 3.6.2 Latin America MRD (Minimal Residual Disease) Testing Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa MRD (Minimal Residual Disease) Testing Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa MRD (Minimal Residual Disease) Testing Sales by Country
    • 3.7.2 Middle East and Africa MRD (Minimal Residual Disease) Testing Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 UAE

4 Global MRD (Minimal Residual Disease) Testing Historic Market Analysis by Type

  • 4.1 Global MRD (Minimal Residual Disease) Testing Sales Market Share by Type (2016-2021)
  • 4.2 Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Type (2016-2021)
  • 4.3 Global MRD (Minimal Residual Disease) Testing Price by Type (2016-2021)

5 Global MRD (Minimal Residual Disease) Testing Historic Market Analysis by Application

  • 5.1 Global MRD (Minimal Residual Disease) Testing Sales Market Share by Application (2016-2021)
  • 5.2 Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Application (2016-2021)
  • 5.3 Global MRD (Minimal Residual Disease) Testing Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 ICON plc
    • 6.1.1 ICON plc Corporation Information
    • 6.1.2 ICON plc Description and Business Overview
    • 6.1.3 ICON plc MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 ICON plc MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.1.5 ICON plc Recent Developments/Updates
  • 6.2 ArcherDX(Invitae)
    • 6.2.1 ArcherDX(Invitae) Corporation Information
    • 6.2.2 ArcherDX(Invitae) Description and Business Overview
    • 6.2.3 ArcherDX(Invitae) MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 ArcherDX(Invitae) MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.2.5 ArcherDX(Invitae) Recent Developments/Updates
  • 6.3 ARUP Laboratories
    • 6.3.1 ARUP Laboratories Corporation Information
    • 6.3.2 ARUP Laboratories Description and Business Overview
    • 6.3.3 ARUP Laboratories MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 ARUP Laboratories MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.3.5 ARUP Laboratories Recent Developments/Updates
  • 6.4 Asuragen
    • 6.4.1 Asuragen Corporation Information
    • 6.4.2 Asuragen Description and Business Overview
    • 6.4.3 Asuragen MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Asuragen MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.4.5 Asuragen Recent Developments/Updates
  • 6.5 Cergentis B.V.
    • 6.5.1 Cergentis B.V. Corporation Information
    • 6.5.2 Cergentis B.V. Description and Business Overview
    • 6.5.3 Cergentis B.V. MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Cergentis B.V. MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.5.5 Cergentis B.V. Recent Developments/Updates
  • 6.6 Bio-Rad Laboratories
    • 6.6.1 Bio-Rad Laboratories Corporation Information
    • 6.6.2 Bio-Rad Laboratories Description and Business Overview
    • 6.6.3 Bio-Rad Laboratories MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 Bio-Rad Laboratories MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.6.5 Bio-Rad Laboratories Recent Developments/Updates
  • 6.7 Mission Bio
    • 6.6.1 Mission Bio Corporation Information
    • 6.6.2 Mission Bio Description and Business Overview
    • 6.6.3 Mission Bio MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Mission Bio MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.7.5 Mission Bio Recent Developments/Updates
  • 6.8 Guardant Health
    • 6.8.1 Guardant Health Corporation Information
    • 6.8.2 Guardant Health Description and Business Overview
    • 6.8.3 Guardant Health MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 Guardant Health MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.8.5 Guardant Health Recent Developments/Updates
  • 6.9 Invivoscribe
    • 6.9.1 Invivoscribe Corporation Information
    • 6.9.2 Invivoscribe Description and Business Overview
    • 6.9.3 Invivoscribe MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 Invivoscribe MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.9.5 Invivoscribe Recent Developments/Updates
  • 6.10 LabCorp
    • 6.10.1 LabCorp Corporation Information
    • 6.10.2 LabCorp Description and Business Overview
    • 6.10.3 LabCorp MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 LabCorp MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.10.5 LabCorp Recent Developments/Updates
  • 6.11 Inivata
    • 6.11.1 Inivata Corporation Information
    • 6.11.2 Inivata MRD (Minimal Residual Disease) Testing Description and Business Overview
    • 6.11.3 Inivata MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.11.4 Inivata MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.11.5 Inivata Recent Developments/Updates
  • 6.12 Natera
    • 6.12.1 Natera Corporation Information
    • 6.12.2 Natera MRD (Minimal Residual Disease) Testing Description and Business Overview
    • 6.12.3 Natera MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.12.4 Natera MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.12.5 Natera Recent Developments/Updates
  • 6.13 NeoGenomics Laboratories
    • 6.13.1 NeoGenomics Laboratories Corporation Information
    • 6.13.2 NeoGenomics Laboratories MRD (Minimal Residual Disease) Testing Description and Business Overview
    • 6.13.3 NeoGenomics Laboratories MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.13.4 NeoGenomics Laboratories MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.13.5 NeoGenomics Laboratories Recent Developments/Updates
  • 6.14 Opko Health
    • 6.14.1 Opko Health Corporation Information
    • 6.14.2 Opko Health MRD (Minimal Residual Disease) Testing Description and Business Overview
    • 6.14.3 Opko Health MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.14.4 Opko Health MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.14.5 Opko Health Recent Developments/Updates
  • 6.15 Quest Diagnostics
    • 6.15.1 Quest Diagnostics Corporation Information
    • 6.15.2 Quest Diagnostics MRD (Minimal Residual Disease) Testing Description and Business Overview
    • 6.15.3 Quest Diagnostics MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.15.4 Quest Diagnostics MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.15.5 Quest Diagnostics Recent Developments/Updates
  • 6.16 Sysmex Corporation
    • 6.16.1 Sysmex Corporation Corporation Information
    • 6.16.2 Sysmex Corporation MRD (Minimal Residual Disease) Testing Description and Business Overview
    • 6.16.3 Sysmex Corporation MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.16.4 Sysmex Corporation MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.16.5 Sysmex Corporation Recent Developments/Updates
  • 6.17 Adaptive Biotechnologies
    • 6.17.1 Adaptive Biotechnologies Corporation Information
    • 6.17.2 Adaptive Biotechnologies MRD (Minimal Residual Disease) Testing Description and Business Overview
    • 6.17.3 Adaptive Biotechnologies MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
    • 6.17.4 Adaptive Biotechnologies MRD (Minimal Residual Disease) Testing Product Portfolio
    • 6.17.5 Adaptive Biotechnologies Recent Developments/Updates

7 MRD (Minimal Residual Disease) Testing Manufacturing Cost Analysis

  • 7.1 MRD (Minimal Residual Disease) Testing Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of MRD (Minimal Residual Disease) Testing
  • 7.4 MRD (Minimal Residual Disease) Testing Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 MRD (Minimal Residual Disease) Testing Distributors List
  • 8.3 MRD (Minimal Residual Disease) Testing Customers

9 MRD (Minimal Residual Disease) Testing Market Dynamics

  • 9.1 MRD (Minimal Residual Disease) Testing Industry Trends
  • 9.2 MRD (Minimal Residual Disease) Testing Growth Drivers
  • 9.3 MRD (Minimal Residual Disease) Testing Market Challenges
  • 9.4 MRD (Minimal Residual Disease) Testing Market Restraints

10 Global Market Forecast

  • 10.1 MRD (Minimal Residual Disease) Testing Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of MRD (Minimal Residual Disease) Testing by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of MRD (Minimal Residual Disease) Testing by Type (2022-2027)
  • 10.2 MRD (Minimal Residual Disease) Testing Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of MRD (Minimal Residual Disease) Testing by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of MRD (Minimal Residual Disease) Testing by Application (2022-2027)
  • 10.3 MRD (Minimal Residual Disease) Testing Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of MRD (Minimal Residual Disease) Testing by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of MRD (Minimal Residual Disease) Testing by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Flow Cytometry
    Polymerase Chain Reaction (PCR)
    Next-Generation Sequencing (NGS)

    Segment by Application
    Specialty Clinics and Hospitals
    Diagnostic Laboratories
    Research Institutions

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    By Company
    ICON plc
    ArcherDX(Invitae)
    ARUP Laboratories
    Asuragen
    Cergentis B.V.
    Bio-Rad Laboratories
    Mission Bio
    Guardant Health
    Invivoscribe
    LabCorp
    Inivata
    Natera
    NeoGenomics Laboratories
    Opko Health
    Quest Diagnostics
    Sysmex Corporation
    Adaptive Biotechnologies

    Buy now